Neurotech International Ltd. · ASX:NTI
Neurotech International — Investor Presentation (July 2022)
18 slides from Neurotech International's investor presentation, Jul 8, 2022
Slide 1: Phase I/II Trial Results Webinar
For personal use only Improving Lives Phase I/II Trial Results Webinar July 2022 Dr Alexandra Andrews Brian Leedman Gerald Quigley PhD Neuroscience, BBMed Sci (Hons1st) BEc, MBA (UWA) B(Pharm) Chief Executive Officer Chairman Non-Executive Director
Slide 2: Disclaimer
Disclaimer For personal use only IMPORTANT INFORMATION Purpose of presentation: This presentation (including this document, any related video or oral These events are, as at the date of this presentation, expected to take place, but there cannot be any presentation, any question and answer session a
Slide 3: Webinar Agenda - 8 July 2022
Webinar Agenda - 8 July 2022 For personal use only 15 minute presentation Dr Alexandra Andrews CEO Brian Leedman Chairman Gerald Quigley Non-Executive Director Brian Leedman Chairman 20 minute live Q & A 3
Slide 4: Neurotech is a biopharmaceutical company
Neurotech is a biopharmaceutical company focused on the development & For personal use only commercialisation of neurological solutions that improve quality of life. Successful Phase I/II World’s first whole Exclusive worldwide Trial 93% of patients plant extract cannabis licence showed improvement
Slide 5: Capital Structure
Capital Structure For personal use only $0.075 ~$52M ~$2.33M Share price Market Cash at bank* (as at 1st July 2022) capitalisation 697M 143M^ Share on issue Options/rights 1. *as at COB 31 March 2022 5 2. ^Options are comprised at various strike prices between $0.005 to $0.09 as at 31 December 2021
Slide 6: What makes NTI164 different?
What makes NTI164 different? For personal use only 6
Slide 7: NTI164 Phase I/II Trials: The Program
NTI164 Phase I/II Trials For personal use only The Program First in human Phase I/II ASD paediatric study (S8) Commenced in May 2021 at Monash Children’s Hospital led by A/Prof. Michael Fahey Open label – single group 14 patients from 8 to 17yo, Level II and III Autism Spectrum Disorder Dose regime
Slide 8: NTI164 Phase I/II Trials: Outcomes
NTI164 Phase I/II Trials For personal use only Outcomes 93% of patients showed improvement Global Improvement Therapeutic Effect (Efficacy Index) 64% of patients "much improved” 2 patients Therapeutic Index Score of 2 Vast Improvement complete or near remission of all symptoms 29% of patients "minim
Slide 9: NTI164 Phase I/II Trials: well-tolerated
NTI164 Phase I/II Trials For personal use only NTI164 was well-tolerated No serious adverse events recorded Across all doses (5, 10, 15 and 20 mg/kg) NTI164 shows promise compared to other current treatments Risperidone Existing prescribed medications for the treatment of symptoms associated with AS
Slide 10: Chief Investigator Professor Fahey comments
Chief Investigator Professor Fahey, For personal use only Monash Children’s Hospital said, “I am very encouraged with these results. We have designed a rigorous study on all fronts to assess the potential application of NTI164 for the treatment of ASD. We are encouraged by the efficacy shown by NTI1
Slide 11: Why target Autism Spectrum Disorders (ASD)?
Why target Autism Spectrum Disorders (ASD)? For personal use only RISPERIDONE US$5.6b2 PREVALENCE OF ASD US ANNUAL TREATMENT ~1 in 44 children SALES US$2.1b3 MARKET SIZE in the US1 US$1.85b4 Ritalin and Concerta Active ingredient Methylphenidate Market Current Treatment Trials ASD is a serious Huge
Slide 12: Current and Future Opportunities for NTI164
Current and Future Opportunities for NTI164 For personal use only CEREBRAL MIGRAINE PALSY COMBINATION THERAPIES AUTISM US$4.4b 3 US$1.7b 5 Prednisone SPECTRUM by 2030 Future Target Diclofenac Future Target & other DISORDER US$2.3b 1 MULTIPLE SCLEROSIS ADHD TRAUMATIC BRAIN Phase I/II completed INJURY
Slide 13: Pathways to Commercialisation
Pathways to Commercialisation For personal use only The anti-inflammatory properties NTI strains in combination with minimal presence of THC (< 0.3%) provides clear pathways to commercialisation: Pharmaceutical Combination • FDA new drug registration • Fast route to commercialisation via • Huge pote
Slide 14: Strong Patent Position
Strong Patent Position For personal use only Neurotech has lodged two Composition strategic provisional patent applications with IP Australia Uniqueness of the NTI-164 strain – composition profile with low THC (<0.3%) to underpin future worldwide and a unique combination of ‘rarer’ commercialisation
Slide 15: NTI164 Development Program Timeline
NTI164 Development Program Timeline For personal use only Commence Phase II/III Registration Study Licensing & (Monash Children’s Commercialisation US based Hospital Department of Discussions Phase II/III study efficacy study Neurology) completion Q3 2022 Q4 Q1 2023 Q2 Q3 Q4 Pre- IND US FDA Drug Mas
Slide 16: Highly Experienced Executive Team and Board
Highly Experienced Executive Team and Board For personal use only Dr Alexandra Andrews Brian Leedman Krista Bates Prof. Allan Cripps AO Mark Davies Winton Willesse Gerald Quigley CEO Chairman Non-Executive Director Non-Executive Director Non-Executive Director Non-Executive Director Non-Executive Di
Slide 17: Why Invest
Why Invest For personal use only Experienced Unique Clinical Significant board and biopharmaceutical programs near term management cannabinoid underway milestones platform targeting pivotal, & newsflow unmet needs 17
Slide 18: Contact Details
For personal use only Contact Details Media: Dr Alexandra Andrews Amalie Schreurs CEO White Noise Communications [email protected] [email protected] +61 405 339 788 +61 (0)431 636 033 www.neurotechinternational.com www.mentetech.com Neurotech International Limited (ASX: NTI) 18
Neurotech International — Investor Presentation (July 2022) on 6ix